Neurotez Inc.'s original offering opened on January 2, 2018 and closed on February 26, 2018. The information on this page was accurate as of February 26, 2018. The most recent price per share on Netcapital is $2.00.

$0.01

$2.00

506

$1.80 — $2.00

From the CEO

“I have personal experience on how devastating a brain disorder that changes your behavior and personality can be. My mother, who died in 2014, suffered from Alzheimer’s. My personal commitment is to develop a cure for Alzheimer’s disease, no matter what this may cost. There is no plan B.”

- Nikolaos Tezapsidis

Problem

Alzheimer’s disease affects more than 5 million Americans and 40 million patients worldwide.

Current medications provide limited relief. Many of our competitors are focusing on removing either Abeta or tau deposits from the brain where they form plaques and tangles. None of these efforts have generated any effective drug for the last 18 years since the first anti-Abeta trial started.

The idea that Abeta and plaque do not cause Alzheimer’s is gaining momentum in the research community. We were determined to look for a different solution prior to the formation of the plaques.

Industry Snapshot

Solution

Our novel approach focuses on Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain.

Hippocampus (in red) responsible for memory formation, cognition and executive function is severely affected by the disease. This region is rich in Leptin receptors.

This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels.

We are developing Memtin™ to treat Leptin deficiency in Alzheimer’s patients. This Leptin product will act as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.

The Biotechnology Industry Organization nominated Neurotez, Inc. as a Most Promising Private Company for its 2015 Buzz of Bio Contest.

Best Presentation Award at NYC Venture Summit 2011

A panel of judges consisting of venture capitalists, private investors and other business executives at the NYC Venture Summit 2011, voted Neurotez’s presentation as the best among 30 companies in the Life sciences category.

2010 Incubator Company to Watch

Neurotez was chosen as a 2010 Incubator Company to Watch at the NJTC Gala Awards

Team

Operating Team

An impressive group of exceptional individuals with deep experience and success in their respective fields in Academia (1000s of publications in Alzheimer’s) and Pharmaceutical Industry have been working together for a number of years to achieve our mission.

Nikolaos Tezapsidis

President and CEO

PhD in Biochemistry at the University of Sussex, UK

18+ years of biomedical research

Two awards from the Alzheimer’s Association

Wes Ashford

Chief Medical Officer

MD and PhD in Neuroscience from UCLA

100+ publications on Alzheimer’s disease

Senior Research Scientist at the Stanford/VA Aging Clinical Research Center and Alzheimer’s Center

George Perry

Chief Science Officer

PhD in Marine Biology from Scripps Institution of Oceanography

1,000+ publications on Alzheimer's disease

Semmes Foundation Endowed Chair in Neurobiology at the University of Texas at San Antonio

Hamish McArthur

Chief Manufacturing Officer

PhD in Microbial Biochemistry at University of Cambridge

33 years of drug development experience at Pfizer

50+ publications and patents

Jukka Karjalainen

COO

25+ years of pharma experience in US, Canada, and Europe

Authored 55 original publications in top-rated international medical journals

Member of International Science Advisory Board

Jane Johnston

VP Operations

PhD in Biochemistry from Imperial College

18+ years of research experience in neural repair and cellular imaging

Principal Investigator for the University of Medicine and Dentistry of New Jersey and Albert Einstein College of Medicine

Pitch Deck

More Info

Use of Proceeds

To be used for General Corporate purposes including legal, accounting, marketing, and salary expenses.

If the offering's maximum amount of $107,000 is raised:

Use

Value

% of Proceeds

Compensation for Directors, Officers, and Promoters

$5,000

4.7%

Debt Repayment

$10,000

9.3%

Marketing

$28,919

27.0%

Legal

$28,919

27.0%

Accounting

$28,919

27.0%

Terms

This is an offering of Common Stock, under registration exemption 4(a)(6), in Neurotez Inc.. This offering must raise at least $10,000 by February 26, 2018 at 4:00pm ET. If this offering doesn’t reach its target, then your money will be refunded. Neurotez Inc. may issue additional securities to raise up to $107,000, the offering’s maximum.

$10,000 minimum

$95,209 raised

If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:

11,122,250 shares

×

$1.00 per share

$11,122,250implied valuation

Financials

These financial statements have been reviewed by an independent Certified Public Accountant.

Transactions

Spread

*Some securities may only be transferred to accredited investors if issued within the past 365 days. Unaccredited investors are permitted to place bids, so some transfers may have yet to occur.

No recent secondary activity

Transaction Log

When

Type

Quantity

Price

No recent transactions

Ask a Question

Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email help@netcapital.com instead of commenting.

Understand the Risks

Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.

Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.

The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Looking to raise capital? We can help turn your firends, family and customers into investors.

Netcapital Systems LLC (Netcapital), which is neither a funding portal nor a broker-dealer, runs this web site. Sections of the web site are used by Netcapital Funding Portal, Inc. to conduct all 4(a)(6) offerings as a funding portal registered with the United States Securities and Exchange Commission (SEC) and as a member of the Financial Industry Regulatory Authority (FINRA). Sections of the web site are used by Livingston Securities, LLC to conduct all 506(c) offerings as a broker-dealer registered with the SEC and as a member of FINRA. None of these companies provide investment advice or make investment recommendations; nothing we post to this web site should be construed as such. Use of this web site constitutes acceptance of Netcapital's Terms of Service.

Neurotez Inc.’s Valuation Method

Our valuation is based on a combination of deals done for companies at this stage, a valuation of our company done by a private equity firm ($8.25 million) and an internal model based on a risk-adjusted net present value, and achieving less than 10% penetration of a $30 billion market opportunity upon approval.

Total Raised

This is an offering of Common Stock, under registration exemption 4(a)(6), in Neurotez Inc.. This offering must raise at least $10,000 by February 26, 2018 at 4:00pm ET. If this offering doesn’t reach its target, then your money will be refunded. Neurotez Inc. may issue additional securities to raise up to $107,000, the offering’s maximum.